Efgartigimod PH20 SC for treating chronic inflammatory demyelinating polyradiculoneuropathy

Efgartigmod PH20 SC are currently in clinical development for the treatment of adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). CIDP is a neurological disorder that leads to progressive weakness and reduced senses in the arms and legs. It is caused by damage to the fat protecting the nerves. Symptoms of CIDP include tingling or no feeling in the fingers or toes, weakness in the arms and legs, loss of reflexes and fatigue. CIDP most commonly occurs between ages 40 and 60, but can also affect children and the elderly, and is more common in men. Treatment options for CIDP are currently limited.